Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026)
Organogenesis Holdings' (ORGO) quarterly Non-Current Assets came in at $251.5 million in Q1 2026, up 26.23% year-on-year from $199.2 million in Q1 2025, and up 6.32% quarter-over-quarter from $236.5 million in Q4 2025.
Organogenesis Holdings (ORGO) Non-Current Assets (2015 - 2026) Analysis & Trends
Organogenesis Holdings' Non-Current Assets history runs 12 years deep, the most recent figure standing at $251.5 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 26.23% year-over-year to $251.5 million in Q1 2026; TTM through Mar 2026 was $899.0 million, a 8.59% increase from a year earlier, with the FY2025 full-year figure at $236.5 million, up 11.61% from the prior year.
- Non-Current Assets grew to $251.5 million in Q1 2026 per ORGO's latest filing, from $236.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $251.5 million in Q1 2026 and bottomed at $199.2 million in Q1 2025.
- The 5-year median for Non-Current Assets is $226.7 million (2022), against an average of $223.0 million.
- Across the five-year window, Non-Current Assets jumped 63.07% in 2022 and fell 13.87% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $226.8 million in 2022, then climbed by 3.63% to $235.0 million in 2023, then fell by 9.8% to $211.9 million in 2024, then increased by 11.61% to $236.5 million in 2025, then grew by 6.32% to $251.5 million in 2026.
- Per Business Quant, the three latest ORGO Non-Current Assets figures stand at $251.5 million (Q1 2026), $236.5 million (Q4 2025), and $210.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Organogenesis Holdings | 310.55 Mn | 218.45 Mn | 11.46 Mn | 251.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.49 Mn |
| Dec 31, 2025 | 236.54 Mn |
| Sep 30, 2025 | 210.08 Mn |
| Jun 30, 2025 | 200.91 Mn |
| Mar 31, 2025 | 199.23 Mn |
| Dec 31, 2024 | 211.95 Mn |
| Sep 30, 2024 | 207.79 Mn |
| Jun 30, 2024 | 208.97 Mn |
| Mar 31, 2024 | 231.31 Mn |
| Dec 31, 2023 | 234.98 Mn |
| Sep 30, 2023 | 237.07 Mn |
| Jun 30, 2023 | 233.88 Mn |
| Mar 31, 2023 | 229.29 Mn |
| Dec 31, 2022 | 226.75 Mn |
| Sep 30, 2022 | 226.75 Mn |
| Jun 30, 2022 | 224.81 Mn |
| Mar 31, 2022 | 218.42 Mn |
| Dec 31, 2021 | 216.28 Mn |
| Sep 30, 2021 | 158.59 Mn |
| Jun 30, 2021 | 153.80 Mn |